Average visceral-fat (abdominal fat) change after 26 weeks in the pivotal Egrifta medicine trial - HIV-associated lipodystrophy patients, under medical supervision - versus +5.0% on placebo. A result belonging to that medicine trial, not a Form Labs product claim.
Falutz 2007 NEJMGHRH analog studied in growth-hormone-axis research
Tesamorelin
A stabilised analog of growth-hormone-releasing hormone, studied for its role in the growth-hormone axis and visceral-fat research. Supplied for laboratory research only.
Your brain sends a short message telling your body to release its own growth hormone. Tesamorelin is a lab-made copy of that message, built to survive longer than the real one. It is also the molecule behind a prescription medicine called Egrifta, which is not what we supply. Supplied freeze-dried, for laboratory research only.
Current lot pricing
$249.00 AUD
Base vial price: $249.00 AUD
Vial size10 mg
Ships from Perth, Australia PostFree standard shipping over $250Plain, discreet packagingStore at 2-8 C
Supplied strictly as reference material for in-vitro laboratory research. Not a medicine, supplement, or food. Not for human or veterinary use.
Research use onlyWhy this molecule is studied
Why researchers study this pathway.
Start with what it copies. Deep in your brain, the hypothalamus releases a hormone called GHRH - growth-hormone-releasing hormone. Its whole job is to travel a short distance to the pituitary gland and tell it to release growth hormone. Tesamorelin is a synthetic copy of that message with a small chemical cap added, which stops it being broken down as fast as the natural version.
That is the entire mechanism, and it is worth being precise about: tesamorelin contains no growth hormone and supplies none. It acts on the switch that makes the body release its own.
Now the part that needs care. This same molecule is the active ingredient in Egrifta, an FDA-approved prescription medicine used for one specific condition - abnormal abdominal fat build-up in people with HIV-associated lipodystrophy. The trial figures quoted on this page come from those medical trials, in that patient group, under medical supervision. They belong to the medicine. They do not belong to the material on this page.
Form Labs does not sell Egrifta. What is on this page is reference material of the tesamorelin molecule for laboratory research - not a medicine, and not for people or animals to take.
The research
What the published studies found.
Average visceral-fat change after 6 months in the second pivotal Egrifta medicine trial, same patient group, versus −0.6% on placebo. A result belonging to that medicine trial, not a Form Labs product claim.
Falutz 2010 JAIDSTesamorelin is an analog of the full 44-amino-acid GHRH hormone (growth-hormone-releasing hormone). An identity fact about the molecule, not a trial result.
Published Tesamorelin researchFigures outside lot paperwork describe third-party research records for the molecule. They are not Form Labs product results or use claims.
Read the full research guideIdentity, papers, and research-use boundariesMechanism notes
Plain-language research labels.
One message, three links in the chain: the switch it presses, the hormone that follows, and the marker researchers measure downstream. This is the published science on the molecule, not a description of what this vial does.
The switch
Your pituitary gland carries a receptor that listens for GHRH - the brain's 'release some growth hormone' message. Tesamorelin is studied as a molecule that fits that same receptor and presses the same switch.
Your own growth hormone
This is the part most often got wrong. Tesamorelin is not growth hormone and contains none. What the papers describe is a compound acting on the switch so the body releases its own - a meaningfully different thing from supplying the hormone itself.
IGF-1
Growth hormone does a lot of its work indirectly, by prompting the liver to make a second signal called IGF-1. Because IGF-1 is steadier and easier to measure than growth hormone itself, researchers track it as their readout of whether the pathway moved at all.
Order anchor
Form Laboratories
Tesamorelin with live bundle pricing.
- Independently tested for purity and identity, with the result printed on the lab report
- A batch number on every vial that matches its lab report, so the paperwork can be checked against the material
- Ships from Perth via Australia Post in plain packaging, with tracking emailed; on arrival, store at 2-8 °C and protect from light
- 30-day purity guarantee: if an independent re-test comes back below the purity on the report, we refund the order in full
Base tier
$249.00 AUD
Single vial / 10 mg / $249.00 AUD per vial
Ships after order review. Reference material for research use only.
Testing documentation
Lot-level records
Australia-wide dispatch
Plain, tracked delivery
Plain fulfilment
Discreet outer packaging
Research use only
No human-use claims
COA proof
Batch paperwork before checkout.
98.1%
Measured purity is matched to the product record and batch paperwork.
Purity test (HPLC) listed at 98.1%Identity confirmedStored at 2-8 °C, protect from light
Certificate of AnalysisTESA-2506
CompoundTesamorelin
LotTESA-2506
Purity98.1%
Net peptide10 mg
AppearanceFreeze-dried reference material
ReleasedCurrent product record
Download COA summary
Build your stack
Study alongside other catalogue references.
These products are shown as catalogue pairings only. Add any line to the same cart for order review.
Dual GIP + GLP-1 research reference
Tirzepatide
$99 AUD
Researchers can study this catalogue reference alongside Tesamorelin in the same order record.
No-DAC and GHS-R1a research set
CJC-1295 (No DAC) & Ipamorelin
$80 AUD
Researchers can study this catalogue reference alongside Tesamorelin in the same order record.
Triple-receptor research peptide
Retatrutide
$149 AUD
Researchers can study this catalogue reference alongside Tesamorelin in the same order record.
FAQ
Questions, answered plainly.
TESA is supplied as laboratory research material only. It is 21+ only, not for human consumption, and not for veterinary use.
Yes. The product page lists lot, identity, purity, appearance, release status, and storage notes for TESA.
Follow the label and matching COA paperwork. This page repeats 2-8 C storage guidance and light-protection notes before checkout.
Tesamorelin is a lab-made peptide known in research as TH9507, a stabilised analog of growth-hormone-releasing hormone. Form Laboratories supplies it freeze-dried as reference material for laboratory research.
Tesamorelin is the active molecule in Egrifta, an FDA-approved prescription medicine. Form Laboratories does not sell Egrifta or any medicine; this material is research-use-only reference material of the molecule, not the approved drug, not for human use.
No. Tesamorelin from Form Laboratories is supplied strictly as reference material for laboratory research, not a medicine, supplement, or food, and not for people or animals to take. Even though the same molecule is an approved prescription medicine elsewhere as Egrifta, this material is not that medicine and is not for human use.
Tesamorelin is approved by the US FDA under the brand name Egrifta (2010) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy - a specific medical condition. It is not registered with Australia's Therapeutic Goods Administration (TGA), and its European approval application was withdrawn. The material sold here is not that approved medicine: it is research-use-only reference material of the molecule, with no approval for any human use.
The approved medicine Egrifta (tesamorelin) is not registered with Australia's Therapeutic Goods Administration (TGA); where it's used in Australia at all, that's only through a doctor's Special Access Scheme application. Form Labs supplies tesamorelin strictly as research-use-only reference material - for laboratory research only, not for human use, and not as a medicine.
In published research, tesamorelin acts on the GHRH receptor - the same receptor the body's own growth-hormone-releasing hormone uses - and is studied for prompting the body to release its own growth hormone (GH), which in turn raises IGF-1. It does not supply growth hormone directly. These describe the scientific literature, not effects claimed for this vial.
Tesamorelin is studied in research for its role in the growth-hormone axis and in body-composition research, particularly visceral (abdominal) fat. Its pivotal human trials looked at visceral fat in people with HIV-associated lipodystrophy, a specific medical condition. On this page those studies are scientific context about the molecule, not claims about what this research material does.
Tesamorelin and CJC-1295 are both lab-made analogs of growth-hormone-releasing hormone (GHRH), but they're different molecules. Tesamorelin keeps the full 44-amino-acid GHRH sequence with a chemical cap that slows its breakdown; CJC-1295 uses a shorter 29-amino-acid fragment, sometimes attached to a carrier that greatly extends how long it lasts. Tesamorelin also has an approved-medicine history (Egrifta) that CJC-1295 doesn't; both are supplied here only as research reference material.
It ships from our base in Perth via Australia Post, in plain packaging with nothing identifying on the outside, once your payment has cleared. You'll get a tracking email. On arrival, store it in the fridge at 2-8 °C and keep it out of light.
Add the size and quantity you want to your cart and check out. Instead of paying by card, you'll get an emailed invoice with our bank details - pay by bank transfer, quoting the reference. Once the payment clears we pack your order and send it, and you'll get a tracking email. A faster transfer (PayID or Osko) gets things moving sooner.
Form your biology
Tesamorelin, with the batch details visible.
Before you order, check the batch number shown on the page against the lab report for that batch.
Added to cart